HER family protein expression and activation predicts response to combination T-DM1/pertuzumab in HER2+ patients in the I-SPY 2 TRIAL.
Julia Wulfkuhle(University of California, San Francisco), Denise M. Wolf, Emanuel Petricoin(George Mason University), Laura van ‘t Veer, Paula R. Pohlmann(The University of Texas MD Anderson Cancer Center), Lamorna Brown Swigart(University of California, San Francisco), Douglas Yee(University of Minnesota Medical Center), Stacy L. Moulder(The University of Texas MD Anderson Cancer Center), Rosa I. Gallagher(George Mason University), Christina Yau(Hospital Authority), Laura J. Esserman(University of California, San Francisco), Donald A. Berry(Berry & Associates (United States)), Gillian L. Hirst(University of California, San Francisco), Anthony Elias(University of Colorado Cancer Center), Angela DeMichele(University of Pennsylvania), Debu Tripathy(The University of Texas MD Anderson Cancer Center)
Cited by 4
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k